Democrats such as Elizabeth Warren had their eye on business and the working class during the first 2020 presidential primary debate in Miami.2020 Electionsread more
The issue over health insurance marked the first stark divide among the candidates, and sparked a heated back-and-forth between many of the candidates on stage.Politicsread more
Huawei's legal chief told CNBC that the company makes "solutions for civil use."Technologyread more
Four candidates mentioned China — but none of the Democratic contenders brought up trade in the debate.Politicsread more
In a strategy to draw attention away from Wednesday's Democratic debate, President Donald Trump's reelection campaign bought out YouTube's "masthead," the leading...2020 Electionsread more
The Federal Aviation Administration said on Wednesday that is has found an issue with the Boeing 737 Max that the manufacturer must address before it lifts the grounding...Airlinesread more
The collapse of the deal potentially ended Sinclair's hopes of building a national conservative-leaning TV powerhouse that might have rivaled Fox News.Mediaread more
Huawei legal chief Song Liuping told CNBC that the company is in the "early phase" of talks with Verizon over paying royalties.Technologyread more
Virginia Sen. Mark Warner breaks down the idea behind a bipartisan bill he introduced to provide more transparency in Big Tech.Technologyread more
U.S. President Donald Trump on Thursday asked India to withdraw retaliatory tariffs that New Delhi imposed this month, calling the duties "unacceptable."World Economyread more
Wi-Fi 6 will be the next-generation wireless standard. Along with 5G, it will represent the next big shift in connectivity and data, said Irving Tan, senior vice president and...Shaping the futureread more
While biotech stocks saw an early selloff Friday, the shares of three companies in the sector have plenty of potential left, John Schroer of Allianz Global Investors said on CNBC.
Biogen Idec is his top pick.
"Leading company in the [multiple sclerosis] space. They have some very strong earnings growth, 20 to 25 percent earnings growth over the next three years. And we're looking at a valuation that's just below 25 times, so it's a very attractive name," said Schroer, who is U.S. sector head of health-care research and a portfolio manager at Allianz.
Read MoreMidday movers: Gilead & more
"I think this is a short-term event," Schroer said. "I would be a buyer of Gilead today."
That stock also was relatively cheap, he added, selling at 11 times consensus earnings.
Schroer said that Gilead hit on several metrics.
"They continue to grow revenues, and they continue to deliver earnings, so those are the types of names that we look for," he said. "There are companies that trade at $200 billion [valuation], so that's not a ceiling."
Celgene is Schroer's third pick.
—By CNBC's Bruno J. Navarro
Disclosure: Schroer's AllianzGI Wellness Fund owns shares of BIIB, GILD and CELG.